Status | Study |
Recruiting |
Study Name: Studies of Dermatologic Diseases Biospecimen Acquisition Protocol Condition: Dermatologic Conditions Healthy Volunteers Normal Voluntee Date: 2015-06-12 |
Recruiting |
Study Name: QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Condition: Stage IIIB Merkel Cell Carcinoma Stage IV Merkel Cell Carcinoma Date: 2015-06-03 Interventions: Biological: aNK (NK-92) A natural killer cell line recovered from a patient with large granular lymphoma |
Recruiting |
Study Name: Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Condition: Carcinoma, Merkel Cell Date: 2015-01-13 Interventions: Drug: Lanreotide Other Name: Somatuline |
Active, not recruiting |
Study Name: Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Condition: Recurrent Merkel Cell Carcinoma Stage IIIA Merkel Cell Carcinoma Date: 2014-10-14 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation Condition: Merkel Cell Carcinoma Date: 2014-06-20 Interventions: Drug: Ipilimumab adjuvant treatment of completely resected Merkel cell carcinoma |
Recruiting |
Study Name: Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Condition: Carcinoma, Merkel Cell Date: 2014-06-02 Interventions: Drug: Avelumab Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour in |
Recruiting |
Study Name: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2014-01-31 Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel |
Active, not recruiting |
Study Name: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2014-01-10 Interventions: Biological: GLA-SE Glucopyranosyl Lipid A in Stable Emulsion |
Active, not recruiting |
Study Name: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Skin Cancer Date: 2013-12-19 Interventions: Drug: Cabozantinib Cabozantinib 60 mg Oral Daily 28 days (4 weeks) |
Withdrawn |
Study Name: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Condition: Merkel Cell Carcinoma Date: 2013-07-28 Interventions: Drug: Ipilimumab Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is comm |